Display options
Cite
Snyder EM, Beck KC, Dietz NM, et al. Arg16Gly polymorphism of the beta2-adrenergic receptor is associated with differences in cardiovascular function at rest and during exercise in humans. J Physiol. 2005;571:121-30doi: 10.1113/jphysiol.2005.098558.
Snyder, E. M., Beck, K. C., Dietz, N. M., Eisenach, J. H., Joyner, M. J., Turner, S. T., & Johnson, B. D. (2006). Arg16Gly polymorphism of the beta2-adrenergic receptor is associated with differences in cardiovascular function at rest and during exercise in humans. The Journal of physiology, 571121-30. https://doi.org/10.1113/jphysiol.2005.098558
Snyder, Eric M, et al. "Arg16Gly polymorphism of the beta2-adrenergic receptor is associated with differences in cardiovascular function at rest and during exercise in humans." The Journal of physiology vol. 571 (2006): 121-30. doi: https://doi.org/10.1113/jphysiol.2005.098558
Snyder EM, Beck KC, Dietz NM, Eisenach JH, Joyner MJ, Turner ST, Johnson BD. Arg16Gly polymorphism of the beta2-adrenergic receptor is associated with differences in cardiovascular function at rest and during exercise in humans. J Physiol. 2006 Feb 15;571:121-30. doi: 10.1113/jphysiol.2005.098558. Epub 2005 Dec 08. PMID: 16339181; PMCID: PMC1805638.
Copy Download .nbib Format: NLM
Share it on

J Physiol. 2006 Feb 15;571:121-30. doi: 10.1113/jphysiol.2005.098558. Epub 2005 Dec 08.

Arg16Gly polymorphism of the beta2-adrenergic receptor is associated with differences in cardiovascular function at rest and during exercise in humans.

The Journal of physiology

Eric M Snyder, Kenneth C Beck, Niki M Dietz, John H Eisenach, Michael J Joyner, Stephen T Turner, Bruce D Johnson

Affiliations

  1. Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, 200 1st Street, SW, Rochester, MN 55905, USA. [email protected]

PMID: 16339181 PMCID: PMC1805638 DOI: 10.1113/jphysiol.2005.098558

Abstract

In humans, subjects homozygous for arginine (ArgArg) at codon 16 of the beta2-adrenergic receptor (beta2AR) have been shown to have greater agonist-mediated desensitization than subjects homozygous for glycine (GlyGly). We sought to determine if this substitution differentially influenced cardiovascular function during short duration (9 min) low and high intensity exercise (40 and 75% of peak work). Healthy Caucasian ArgArg (n = 16), GlyGly (n = 31) and ArgGly (n = 17) subjects matched for age, sex and peak oxygen uptake were studied. There were no differences in adrenaline (ADR) at rest or with heavy exercise, but the ArgArg group had lower ADR with light exercise (P = 0.04). Resting heart rate (HR) was higher in ArgArg (P < 0.01), while cardiac output (Q), stroke volume (SV), and mean arterial pressure (MAP) were lower than the other groups (HR = 86+/-2, 78+/-2, 80+/-1 beats min(-1); Q = 5.7+/-0.81, 6.1+/-0.18, 6.7+/-0.22 l min(-1); SV = 68+/-3, 82+/-3, 89+/-4 ml beat(-1); MAP = 92+/-1, 103+/-2, 98+/-1 mmHg-- for ArgArg, ArgGly and GlyGly, respectively, means +/-s.e.m., P < 0.01), however, no differences were observed in systemic vascular resistance (SVR). With low intensity exercise and high intensity exercise the ArgArg group continued to have a lower , SV and MAP compared to the other groups (P < 0.05), with no differences observed in SVR. During recovery, the ArgArg subjects continued to have a lower MAP but there were no differences in HR, , or SVR. These data suggest that subjects homozygous for Arg at codon 16 of the beta2AR have reduced and MAP at rest that persist during exercise with no evidence for differential changes over the course of exercise despite large changes in catecholamines. This may suggest possible genotype-related differences in baseline receptor function or density which causes phenotypic differences at rest that are sustained during short-term exercise.

References

  1. J Cardiovasc Electrophysiol. 1996 Nov;7(11):1039-49 - PubMed
  2. Pulm Pharmacol. 1995 Feb;8(1):1-10 - PubMed
  3. J Mol Cell Cardiol. 1997 Mar;29(3):961-7 - PubMed
  4. Kidney Int. 1998 Jun;53(6):1455-60 - PubMed
  5. J Mol Cell Cardiol. 1998 May;30(5):1037-45 - PubMed
  6. J Biol Chem. 1999 Jun 11;274(24):16694-700 - PubMed
  7. Med Hypotheses. 2005;65(2):296-9 - PubMed
  8. J Appl Physiol (1985). 2000 May;88(5):1650-8 - PubMed
  9. Clin Pharmacol Ther. 2000 Jun;67(6):670-5 - PubMed
  10. Circulation. 2000 Jun 27;101(25):2877-82 - PubMed
  11. Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10483-8 - PubMed
  12. Hypertension. 2000 Sep;36(3):371-5 - PubMed
  13. Clin Exp Pharmacol Physiol. 2001 May-Jun;28(5-6):364-70 - PubMed
  14. N Engl J Med. 2001 Oct 4;345(14):1030-5 - PubMed
  15. J Hypertens. 2002 Feb;20(2):229-35 - PubMed
  16. Am J Pharmacogenomics. 2001;1(3):165-74 - PubMed
  17. Circulation. 2002 Jul 16;106(3):349-55 - PubMed
  18. Trends Cardiovasc Med. 2002 Oct;12(7):287-94 - PubMed
  19. J Physiol. 2003 Jan 15;546(Pt 2):583-9 - PubMed
  20. Hypertension. 2003 Oct;42(4):685-92 - PubMed
  21. Am J Hypertens. 2003 Nov;16(11 Pt 1):945-51 - PubMed
  22. Physiol Genomics. 2004 Feb 13;16(3):323-8 - PubMed
  23. Am J Physiol Heart Circ Physiol. 2004 Sep;287(3):H1029-38 - PubMed
  24. Am J Physiol Renal Physiol. 2004 Oct;287(4):F639-48 - PubMed
  25. J Cardiovasc Pharmacol. 1982 Nov-Dec;4(6):903-14 - PubMed
  26. J Pharmacol Exp Ther. 1984 Mar;228(3):733-8 - PubMed
  27. Hypertension. 1986 Feb;8(2):133-41 - PubMed
  28. Cardiovasc Res. 1987 Feb;21(2):124-9 - PubMed
  29. Mol Pharmacol. 1989 Mar;35(3):295-303 - PubMed
  30. Life Sci. 1989;45(22):2061-76 - PubMed
  31. Pharmacol Rev. 1991 Jun;43(2):203-42 - PubMed
  32. Clin Chem. 1991 Oct;37(10 Pt 2):1811-9 - PubMed
  33. Am J Physiol. 1992 Sep;263(3 Pt 1):C623-7 - PubMed
  34. J Biol Chem. 1993 Nov 5;268(31):23116-21 - PubMed
  35. Biochemistry. 1994 Aug 16;33(32):9414-9 - PubMed
  36. J Appl Physiol (1985). 1996 Dec;81(6):2495-9 - PubMed

Substances

MeSH terms

Publication Types

Grant support